The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl each (A), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, -CH2C(=O)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl X is 0, 1, 2, or 3 (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B) (Z) is -NH- (L) is chosen from a single bond, -CH2-, -CH2CH2-, -CH2CH2CH2-, and -CH2CH2CH2CH2- and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from - NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. A′x−A−B−Z−L−DThe compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.
